Chris Aiken, MD

Chronic Depression with Allen Frances

December 30, 2024

Kellie Newsome, PMHNP, Allen Frances, MD, and Chris Aiken, MD

Allen Frances shares his approach to chronic depression.

Building a Better Alliance with Allen Frances

December 23, 2024

Kellie Newsome, PMHNP, Allen Frances, MD, and Chris Aiken, MD

Allen Frances shows us how to adjust our therapeutic approach for problems that are simple and those a bit more complex.

The Simple and the Complex in Psychiatry with Allen Frances

December 16, 2024

Kellie Newsome, PMHNP, Chris Aiken, MD, and Allen Frances, MD

Allen Frances shows us how to adjust our therapeutic approach for problems that are simple and those a bit more complex.

What’s Wrong with Mental Health Care?

December 9, 2024

Kellie Newsome, PMHNP, Chris Aiken, MD, and Nicholas Rosenlicht, MD

We talk with Nick Rosenlicht, MD about what’s gone wrong in the mental health care system.

When Bipolar and ADHD Overlap: Treatment 2

December 2, 2024

Kellie Newsome, PMHNP and Chris Aiken, MD

How to treat ADHD in bipolar disorder without destabilizing mood part 1: stimulants and non-stimulants.

When Bipolar and ADHD Overlap: Treatment 1

November 25, 2024

Kellie Newsome, PMHNP and Chris Aiken, MD

How to treat ADHD in bipolar disorder without destabilizing mood part 1: stimulants and non-stimulants.

When Bipolar and ADHD Overlap: Diagnosis

November 18, 2024

Kellie Newsome, PMHNP and Chris Aiken, MD

You’ll never be 100% sure if a patient has bipolar, ADHD, or both, but we’ll get you as close as we can.

Psychopharm Secrets: What Patients Won’t Tell You

November 4, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

How to assess med response when the patient reports is a poor guide: long-term mood stabilizers, sleep meds, and rapid cycling.

News of Note

Azstarys: Vyvanse’s Dexmethylphenidate Cousin

November 1, 2024

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report.

Dr. Aiken has no financial relationships with companies related to this material.

Azstarys is methylphenidate's answer to Vyvanse. But how does its abuse potential compare?

Clinical Update

Vyvanse Goes Generic: An Amphetamine Apart

November 1, 2024

David Liebers, MD and Chris Aiken, MD

David Liebers, MD. Psychiatry resident at NYU Langone, Department of Psychiatry.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Liebers and Dr. Aiken have no financial relationships with companies related to this material.

Known for lower misuse potential and a smoother effect profile, lisdexamfetamine stands out in ADHD treatment. This article explores what makes it unique among stimulants.